Binge Eating clinical trials

Explore recruiting binge eating clinical trials.

Recruiting binge eating studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Binge Eating trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder.

France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity_PHACYLOB.

France

Therapeutic use (Phase IV) EU CTIS Study details

A neuropsychobiological approach to optimize patient selection for GLP-1-based pharmacotherapy for weight management across the binge eating spectrum

Belgium

Therapeutic use (Phase IV) EU CTIS Study details

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with VENVANSE (lisdexamfetamine dimesylate) 70 mg Hard Gelatin Capsule, imported and registered by: Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. Adm. Jaguariúna-SP CNPJ 60.397.775/0001-74 and manufactured by: Patheon Pharmaceuticals Inc. Cincinnati, United States of America or Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. QC - Jaguariúna – SP, Brazilian industry in healthy adult, human subjects under fasting condition.

Romania

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Binge Eating trials by city

Binge Eating in Toronto Binge Eating in Vancouver Binge Eating in Montreal Binge Eating in Calgary Binge Eating in Edmonton Binge Eating in Ottawa Binge Eating in Winnipeg Binge Eating in Quebec City Binge Eating in Hamilton Binge Eating in Kitchener Binge Eating in London Binge Eating in Halifax Binge Eating in New York Binge Eating in Los Angeles Binge Eating in Chicago Binge Eating in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease